Log in

Relevant bibliographies by topics / Inhibitor / Books

Books on the topic 'Inhibitor'

To see the other types of publications on this topic, follow the link: Inhibitor.

Author: Grafiati

Published: 4 June 2021

Last updated: 29 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 books for your research on the topic 'Inhibitor.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Li, Rongshi, and Jeffrey A. Stafford, eds. Kinase Inhibitor Drugs. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2009. http://dx.doi.org/10.1002/9780470524961.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

A, Stafford Jeffrey, ed. Kinase inhibitor drugs. Hoboken, N.J: J. Wiley, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Chang, Henry E. HIV protease inhibitor report. 2nd ed. Brooklyn, NY (72 Orange St., #3C, Brooklyn 11201): National AIDS Treatment Advocacy Project, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Bashein, Abdulla Masood. Vitreous-derived inhibitor of angiogenesis. Manchester: University of Manchester, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

C, Shirley Anne, ed. Trends in serotonin uptake inhibitor research. Hauppauge, NY: Nova Science Pub., 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Krämer, Oliver H., ed. HDAC/HAT Function Assessment and Inhibitor Development. New York, NY: Springer US, 2023. http://dx.doi.org/10.1007/978-1-0716-2788-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Krämer, Oliver H., ed. HDAC/HAT Function Assessment and Inhibitor Development. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-6527-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Lendeckel, Uwe, and Nigel M. Hooper, eds. Viral Proteases and Antiviral Protease Inhibitor Therapy. Dordrecht: Springer Netherlands, 2009. http://dx.doi.org/10.1007/978-90-481-2348-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Miskei, Gyorgy Zsolt. Studies on lung lavage alphai proteinase inhibitor. Birmingham: University of Birmingham, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

H, Kennedy Sidney, ed. Clinical advances in monoamine oxidase inhibitor therapies. Washington, DC: American Psychiatric Press, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

11

Iqbal, Choudhary Muhammad, ed. Biological inhibitors. Amsterdam: Harwood Academic Publishers, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

12

Helmsen, Sabine. Protein-Ligand-, Protein-Inhibitor- und Protein-Protein-Wechselwirkungen. Wiesbaden: Springer Fachmedien Wiesbaden, 2020. http://dx.doi.org/10.1007/978-3-658-30151-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Mullen, Elizabeth Anne. An inhibitor of angiogenesis isolated from bovine cornea. [s.l: s.n.], 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

14

Seeney, A. A study of molybdate as a corrosion inhibitor. Birmingham: University of Birmingham, 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

15

König, Birgit. Biologisch aktive Polypeptide in Meeresschwämmen: Ein Kallikrein-Inhibitor. [s.l.]: [s.n.], 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

16

Bond, Charles S. Trypanothione reductase: structure, specificity and approaches to inhibitor identification. Manchester: University of Manchester, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

17

C, Moellering Robert, ed. Therapeutic implications of treatment with beta-lactamase inhibitor combinations. Montreal: PharmaLibri Publishers, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

18

Chen, Ginny. Analysis of Saccharomyces cerevisiae cyclin dependent kinase inhibitor Far1. Ottawa: National Library of Canada, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

19

Estrada, Sergio. Cystatin A, a mammalian cysteine proteinase inhibitor: Mechanism of inhibition of target proteinases by recombinant cystatin A variants. Uppsala: Sveriges Lantbruksuniversitet, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

20

Mendonça Teixeira, Alexandre, Lara de Oliveira Arinelli, José Luiz de Medeiros, and Ofélia de Queiroz Fernandes Araújo. Monoethylene Glycol as Hydrate Inhibitor in Offshore Natural Gas Processing. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-66074-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Storm, Detlef. Untersuchung von "clearance"-Mechanismen für C1-Inhibitor-C1-Esterase-Komplexe. [s.l.]: [s.n.], 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

22

Kjaeldgaard, Marianne. Studies on tissue plasminogen activator and its inhibitor in human saliva. Stockholm: Kongl. Carolinska Medico Chirurgiska Institutet, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

23

Kjaeldgaard, Marianne. Studies on tissue plasminogen activator and its inhibitor in human saliva. [S.l: s.n.], 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

24

Reynolds, Alastair. Inhibitor Phase. Orbit, 2021.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

25

Reynolds, Alastair. Inhibitor Phase. Orbit, 2021.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

26

Reynolds, Alastair. Inhibitor Phase. Hachette Book Group and Blackstone Publishing, 2021.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

27

Reynolds, Alastair. Inhibitor Phase. Orion Publishing Group, Limited, 2021.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

28

Inhibitor Phase. London, UK: Orion Publishing Group, Limited, 2022.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

29

Inhibitor Phase. Orbit, 2021.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

30

Purich, Daniel L. The Inhibitor Index. CRC Press, 2017. http://dx.doi.org/10.1201/9781315184289.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Li, Rongshi, and Jeffrey A. Stafford. Kinase Inhibitor Drugs. Wiley & Sons, Incorporated, John, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

32

Li, Rongshi, and Jeffrey A. Stafford. Kinase Inhibitor Drugs. Wiley & Sons, Incorporated, John, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

33

Li, Rongshi, and Jeffrey A. Stafford. Kinase Inhibitor Drugs. Wiley & Sons, Incorporated, John, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

34

Kinase Inhibitor Drugs. Wiley & Sons, Incorporated, John, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

35

Fleischmann, Roy. Signalling pathway inhibitors. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0081.

Full text

Abstract:

Oral, small-molecule signalling pathway inhibitors, including ones that inhibit the JAK and SyK pathways, are currently in development for the treatment of rheumatoid arthritis (RA). Tofacitinib is an orally administered small-molecule inhibitor that targets the intracellular Janus kinase 3 and 1 (JAK1/3) molecules to a greater extent than JAK2 while baricitinib (formerly INCB028050) predominantly inhibits JAK1/2. Many of the proinflammatory cytokines implicated in the pathogenesis of RA utilize cell signalling that involves the JAK-STAT pathways and therefore inhibition of JAK-STAT signalling, by targeting multiple RA-associated cytokine pathways, has the potential to simultaneously reduce inflammation, cellular activation, and proliferation of key immune cells. Fostamatinib disodium is an orally available inhibitor of spleen tyrosine kinase (SyK), which is a cytoplasmic tyrosine kinase that is an important mediator of immunoreceptor signalling in mast cells, macrophages, neutrophils, and B cells. Interruption of SyK signalling may interrupt production of tumour necrosis factor (TNF) and metalloproteinase and therefore affect RA disease activity. Tofacitinib has been investigated in multiple phase 2 and phase 3 trials which have investigated its efficacy (clinical, functional, and radiographic) and safety in patients who have failed disease-modifying anti-inflammatory drugs (DMARDs) as monotherapy or in combination with DMARDs, compared to an inhibitor of tumour necrosis factor alpha (TNFα‎) and in patients who have failed TNFα‎ inhibitors. The efficacy of fostamatinib and baricitinib has been investigated in phase 2 trials; both are in large phase 3 clinical programmes. Each of these medications has demonstrated efficacy; their safety profile has been shown to be different from each other and from currently approved biological agents. This chapter discusses what is currently known and understood about their efficacy and safety.

APA, Harvard, Vancouver, ISO, and other styles

36

COX-2 Inhibitor Research. Nova Science Publishers, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

37

Howardell, Maynard J. Cox-2 Inhibitor Research. Nova Science Publishers, Incorporated, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

38

Enzyme Inhibitor from Marine Organisms. MDPI, 2020. http://dx.doi.org/10.3390/books978-3-03943-784-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Duffy, J. A. The Inhibitor: The Stansfield House. iUniverse Publishing, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

40

Musumeci, Francesca, ed. Kinase Inhibitor for Cancer Therapy. MDPI, 2024. http://dx.doi.org/10.3390/books978-3-7258-1289-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Enzyme Inhibitor from Marine Organisms. Mdpi AG, 2020.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

42

Lawrence, Daniel A. Plasminogen activator inhibitor type 1. Unit for Applied Celland Molecualr Biology, UMEA University, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

43

Trends in Serotonin Uptake Inhibitor Research. Nova Biomedical Books, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

44

Problems With Protease Inhibitor Development Plans. Diane Pub Co, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

45

Thuveson, Maria. Intracellular Processing of Pre-A-Inhibitor. Uppsala Universitet, 1999.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

46

Colo.) Corrosion 9 (1996 Denver. Reviews on Corrosion Inhibitor Science & Technology. N A C E International, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

47

Raman. Reviews on Corrosion Inhibitor Science & Technology. Natl Assn of Corrosion, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

48

Howardell, Maynard J. Trends in Cox-2 Inhibitor Research. Nova Science Publishers, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

49

Reynolds, Alastair. Inhibitor Phase: A Revelation Space Novel. Orion Publishing Group, Limited, 2021.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

50

Kramer, Carolyn, and Emily Blumberg. Immunosuppressants and Antiretroviral Therapy in HIV-Positive Transplant Patients. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190493097.003.0028.

Full text

Abstract:

Protease inhibitors (PIs), especially ritonavir, are inhibitors of CYP3A4 and P-gp1 and can significantly increase levels of calcineurin inhibitors and mammalian target of rapamycin (mTOR) inhibitors. Cobicistat is an inhibitor of CYP3A4, and its effect on levels of calcineurin inhibitors and mTOR inhibitors is likely to be similar to that of ritonavir. Efavirenz may result in lower concentrations of calcineurin inhibitors and mTOR inhibitors. Dose reduction and careful attention to monitoring drug levels are critical to avoid toxicity and maintain therapeutic immunosuppressive concentrations when PIs or cobicistat are coadministered with calcineurin inhibitors or mTOR inhibitors. Although there is no formalized recommendation for the ideal antiretroviral therapy regimen in HIV-positive transplant recipients, a regimen consisting of two nucleoside reverse transcriptase and an integrase inhibitor minimizes the risk of drug–drug interactions and simplifies dosing of immunosuppressive agents while maintaining a high barrier to resistance.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!